Free Trial
→ $2 Trillion Disappears Because of Fed's Secretive New Move (From Stansberry Research) (Ad) Buy KALV Stock  Free KALV Stock Alerts

KalVista Pharmaceuticals (KALV) Financials

KalVista Pharmaceuticals logo
$12.45 +0.15 (+1.22%)
Closing price 04/23/2025 04:00 PM Eastern
Extended Trading
$12.48 +0.03 (+0.20%)
As of 04/23/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for KalVista Pharmaceuticals

Annual Income Statements for KalVista Pharmaceuticals

This table shows KalVista Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -82 -93 -127
Consolidated Net Income / (Loss)		 -82 -93 -127
Net Income / (Loss) Continuing Operations		 -82 -93 -127
Total Pre-Tax Income 		-82 -93 -127
Total Operating Income		 -97 -111 -140
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 97 111 140
Selling, General & Admin Expense		 26 31 54
Research & Development Expense		 70 80 86
Total Other Income / (Expense), net		 14 18 14
Interest & Investment Income		 1.09 2.23 3.90
Other Income / (Expense), net		 13 16 9.91
Income Tax Expense		 0.00 0.00 0.00
Basic Earnings per Share		 ($3.36) ($3.33) ($3.44)
Weighted Average Basic Shares Outstanding		 24.47M 27.89M 36.79M
Diluted Earnings per Share		 ($3.36) ($3.33) ($3.44)
Weighted Average Diluted Shares Outstanding		 24.47M 27.89M 36.79M
Weighted Average Basic & Diluted Shares Outstanding		 24.57M 34.23M 42.74M

Quarterly Income Statements for KalVista Pharmaceuticals

This table shows KalVista Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Net Income / (Loss) Attributable to Common Shareholders		 -23 -22 -21 -26 -25 -28 -29 -45 -40 -42 -49
Consolidated Net Income / (Loss)		 -23 -22 -21 -26 -25 -28 -29 -45 -40 -42 -49
Net Income / (Loss) Continuing Operations		 -23 -22 -21 -26 -25 -28 -29 -45 -40 -42 -49
Total Pre-Tax Income 		-23 -22 -21 -26 -25 -28 -29 -45 -40 -42 -44
Total Operating Income		 -26 -26 -27 -32 -29 -30 -33 -48 -44 -46 -43
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 26 26 27 32 29 30 33 48 44 46 43
Selling, General & Admin Expense		 8.13 7.81 6.88 7.78 9.79 11 11 23 18 29 30
Research & Development Expense		 18 18 20 24 19 19 23 25 27 17 13
Total Other Income / (Expense), net		 3.27 3.63 5.64 5.42 3.78 2.10 4.12 3.81 3.77 3.54 -1.32
Interest Expense		 - - - - - - 0.00 - - - 2.84
Interest & Investment Income		 0.24 0.45 0.73 0.81 0.92 0.78 0.68 1.51 1.69 1.36 1.39
Other Income / (Expense), net		 3.03 3.18 4.91 4.61 2.85 1.32 3.44 2.29 2.08 2.19 0.13
Income Tax Expense		 - - - - - - 0.00 - - - 4.25
Basic Earnings per Share		 ($0.94) ($0.90) ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92)
Weighted Average Basic Shares Outstanding		 24.56M 24.60M 28.28M 27.89M 34.41M 34.57M 34.72M 36.79M 46.23M 46.70M 52.64M
Diluted Earnings per Share		 ($0.94) ($0.90) ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92)
Weighted Average Diluted Shares Outstanding		 24.56M 24.60M 28.28M 27.89M 34.41M 34.57M 34.72M 36.79M 46.23M 46.70M 52.64M
Weighted Average Basic & Diluted Shares Outstanding		 24.60M 24.62M 34.17M 34.23M 34.40M 34.56M 42.19M 42.74M 43.22M 49.42M 49.72M

Annual Cash Flow Statements for KalVista Pharmaceuticals

This table details how cash moves in and out of KalVista Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents		 -20 26 -24
Net Cash From Operating Activities		 -78 -75 -89
Net Cash From Continuing Operating Activities		 -79 -75 -89
Net Income / (Loss) Continuing Operations		 -82 -93 -127
Consolidated Net Income / (Loss)		 -82 -93 -127
Depreciation Expense		 0.56 0.72 0.82
Amortization Expense		 2.57 0.99 0.09
Non-Cash Adjustments To Reconcile Net Income		 13 6.21 30
Changes in Operating Assets and Liabilities, net		 -12 9.73 6.99
Net Cash From Investing Activities		 58 41 -85
Net Cash From Continuing Investing Activities		 58 41 -85
Purchase of Property, Plant & Equipment		 -0.93 -1.20 -0.44
Purchase of Investments		 -137 -98 -189
Sale and/or Maturity of Investments		 196 141 105
Net Cash From Financing Activities		 1.58 58 151
Net Cash From Continuing Financing Activities		 1.58 58 151
Issuance of Common Equity		 1.58 58 151
Effect of Exchange Rate Changes		 -1.17 1.24 -1.21

Quarterly Cash Flow Statements for KalVista Pharmaceuticals

This table details how cash moves in and out of KalVista Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Net Change in Cash & Equivalents		 7.13 0.72 46 -29 -6.83 8.26 -35 8.73 0.06 9.73 126
Net Cash From Operating Activities		 -23 -21 -9.29 -23 -27 -20 -28 -15 -40 -40 -33
Net Cash From Continuing Operating Activities		 -23 -21 -9.29 -23 -27 -20 -28 -15 -40 -40 -33
Net Income / (Loss) Continuing Operations		 -23 -22 -21 -26 -25 -28 -29 -45 -40 -42 -49
Consolidated Net Income / (Loss)		 -23 -22 -21 -26 -25 -28 -29 -45 -40 -42 -49
Depreciation Expense		 0.16 0.17 0.20 0.19 0.19 0.20 0.21 0.22 0.22 0.23 0.23
Amortization Expense		 0.39 0.29 0.21 0.10 0.06 0.02 0.01 0.00 0.01 0.01 2.93
Non-Cash Adjustments To Reconcile Net Income		 3.11 1.43 3.79 -2.12 2.55 -0.31 0.17 27 2.30 2.18 7.92
Changes in Operating Assets and Liabilities, net		 -3.36 -0.23 7.81 5.50 -4.22 7.92 1.07 2.22 -2.31 0.21 4.76
Net Cash From Investing Activities		 30 20 -2.52 -6.21 20 29 -6.70 -126 37 49 8.52
Net Cash From Continuing Investing Activities		 30 20 -2.52 -6.21 20 29 -6.70 -126 37 49 8.52
Purchase of Property, Plant & Equipment		 -0.92 -0.19 -0.02 -0.07 -0.01 -0.21 -0.11 -0.12 -0.09 -0.20 -0.13
Purchase of Investments		 -10 - -54 -34 -26 -3.77 -18 -142 -0.98 -0.00 -6.56
Sale and/or Maturity of Investments		 41 20 51 28 45 33 12 15 38 49 15
Net Cash From Financing Activities		 0.17 0.17 58 -0.03 0.20 0.13 0.28 150 3.00 0.30 152
Net Cash From Continuing Financing Activities		 0.17 0.17 58 -0.03 0.20 0.13 0.28 150 3.00 0.30 152
Issuance of Common Equity		 0.17 0.17 58 -0.03 0.20 0.13 0.28 150 3.00 0.30 57
Effect of Exchange Rate Changes		 -0.34 1.05 0.46 0.07 0.08 -0.60 -0.62 -0.07 0.12 0.41 -1.25

Annual Balance Sheets for KalVista Pharmaceuticals

This table presents KalVista Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets		 204 183 235
Total Current Assets		 194 172 226
Cash & Equivalents		 31 56 32
Short-Term Investments		 135 93 179
Prepaid Expenses		 13 6.38 6.85
Other Current Assets		 14 17 8.44
Plant, Property, & Equipment, net		 2.18 2.95 2.23
Total Noncurrent Assets		 8.06 7.93 7.49
Other Noncurrent Operating Assets		 8.06 7.93 7.49
Total Liabilities & Shareholders' Equity		 204 183 235
Total Liabilities		 19 22 29
Total Current Liabilities		 12 15 23
Accounts Payable		 3.64 4.82 9.11
Accrued Expenses		 6.96 9.13 12
Other Current Liabilities		 0.98 1.09 1.30
Total Noncurrent Liabilities		 7.21 7.15 6.02
Capital Lease Obligations		 - - 6.02
Other Noncurrent Operating Liabilities		 7.21 7.15 0.00
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 185 161 207
Total Preferred & Common Equity		 185 161 207
Total Common Equity		 185 161 207
Common Stock		 439 507 680
Retained Earnings		 -250 -343 -470
Accumulated Other Comprehensive Income / (Loss)		 -3.86 -3.06 -3.49

Quarterly Balance Sheets for KalVista Pharmaceuticals

This table presents KalVista Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Total Assets		 182 163 203 160 139 114 200 161 276
Total Current Assets		 170 151 192 150 129 104 192 152 267
Cash & Equivalents		 38 39 85 49 58 23 32 42 167
Short-Term Investments		 104 84 87 74 46 53 142 94 86
Prepaid Expenses		 11 8.91 8.56 7.53 5.46 5.51 7.45 5.41 6.67
Other Current Assets		 17 20 12 19 20 23 9.91 11 7.49
Plant, Property, & Equipment, net		 3.03 3.06 3.04 2.81 2.50 2.42 2.10 2.04 1.81
Total Noncurrent Assets		 8.88 8.56 8.30 7.68 7.64 7.44 6.46 6.53 6.83
Other Noncurrent Operating Assets		 8.88 8.56 8.30 7.68 7.64 7.44 6.46 6.53 6.83
Total Liabilities & Shareholders' Equity		 182 163 203 160 139 114 200 161 276
Total Liabilities		 18 19 19 21 24 25 27 27 131
Total Current Liabilities		 9.73 11 12 14 18 19 22 22 26
Accounts Payable		 2.91 3.38 1.70 5.06 4.90 3.10 11 5.20 5.86
Accrued Expenses		 5.83 6.91 8.85 7.95 12 15 10 15 18
Other Current Liabilities		 1.00 1.03 1.06 1.12 1.15 1.19 1.26 1.54 1.44
Total Noncurrent Liabilities		 8.01 7.71 7.42 6.87 6.55 6.26 4.99 4.68 105
Capital Lease Obligations		 - - - - - - - 4.68 4.34
Other Noncurrent Operating Liabilities		 8.01 7.71 7.42 6.87 6.55 6.26 4.99 - 101
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 165 144 184 139 114 89 173 134 145
Total Preferred & Common Equity		 165 144 184 139 114 89 173 134 145
Total Common Equity		 165 144 184 139 114 89 173 134 145
Common Stock		 442 445 505 511 514 517 686 689 748
Retained Earnings		 -273 -295 -317 -368 -396 -425 -510 -552 -601
Accumulated Other Comprehensive Income / (Loss)		 -4.15 -5.33 -3.54 -2.89 -3.47 -3.29 -2.87 -2.70 -2.21

Annual Metrics and Ratios for KalVista Pharmaceuticals

This table displays calculated financial ratios and metrics derived from KalVista Pharmaceuticals' official financial filings.

Metric 2022 2023 2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -68.63% -16.35% -38.74%
EBIT Growth		 -70.82% -14.04% -37.21%
NOPAT Growth		 -66.80% -14.76% -26.67%
Net Income Growth		 -78.05% -12.83% -36.31%
EPS Growth		 -38.84% 0.89% -3.30%
Operating Cash Flow Growth		 -158.97% 3.68% -18.56%
Free Cash Flow Firm Growth		 -138.79% 10.08% -17.73%
Invested Capital Growth		 128.59% -38.33% -132.78%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -10.08% -3.42% -17.29%
EBIT Q/Q Growth		 -9.76% -2.96% -17.08%
NOPAT Q/Q Growth		 -9.98% -4.64% -13.52%
Net Income Q/Q Growth		 -12.51% -2.42% -16.94%
EPS Q/Q Growth		 -10.16% 6.72% -10.26%
Operating Cash Flow Q/Q Growth		 -25.23% 5.23% 7.78%
Free Cash Flow Firm Q/Q Growth		 -17.88% 4.62% 4.61%
Invested Capital Q/Q Growth		 43.69% -8.67% -129.38%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00%
Interest Burden Percent		 98.69% 97.65% 97.02%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -37.23% -53.69% -68.90%
Cash Return on Invested Capital (CROIC)		 -576.37% -460.81% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -37.23% -53.69% -68.90%
Return on Equity Simple (ROE_SIMPLE)		 -44.49% -57.70% -61.30%
Net Operating Profit after Tax (NOPAT)		 -68 -78 -98
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -7.09% -9.69% -15.75%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -83 -95 -131
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -80 -93 -130
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.69 1.81 2.32
Price to Tangible Book Value (P/TBV)		 1.69 1.81 2.32
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 7.74 12.20 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.94 -0.91 -0.98
Leverage Ratio		 1.08 1.12 1.14
Compound Leverage Factor		 1.06 1.09 1.10
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 7.98 4.58 6.38
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 16.73 11.46 9.90
Quick Ratio		 14.36 9.94 9.23
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -78 -70 -83
Operating Cash Flow to CapEx		 -8,392.48% -6,292.73% -20,142.44%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 19 12 -3.82
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 11 -7.24 -15
Enterprise Value (EV)		 146 142 268
Market Capitalization		 312 291 479
Book Value per Share		 $7.54 $4.71 $4.90
Tangible Book Value per Share		 $7.54 $4.71 $4.90
Total Capital		 185 161 207
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -166 -149 -210
Capital Expenditures (CapEx)		 0.93 1.20 0.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 16 7.92 -7.52
Debt-free Net Working Capital (DFNWC)		 182 157 203
Net Working Capital (NWC)		 182 157 203
Net Nonoperating Expense (NNE)		 15 15 28
Net Nonoperating Obligations (NNO)		 -166 -149 -210
Total Depreciation and Amortization (D&A)		 3.13 1.71 0.91
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($3.36) ($3.33) ($3.44)
Adjusted Weighted Average Basic Shares Outstanding		 24.47M 27.89M 36.79M
Adjusted Diluted Earnings per Share		 ($3.36) ($3.33) ($3.44)
Adjusted Weighted Average Diluted Shares Outstanding		 24.47M 27.89M 36.79M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 24.57M 34.23M 42.74M
Normalized Net Operating Profit after Tax (NOPAT)		 -68 -78 -98
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for KalVista Pharmaceuticals

This table displays calculated financial ratios and metrics derived from KalVista Pharmaceuticals' official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -46.70% -16.22% 1.35% -13.00% -14.30% -26.80% -36.42% -71.24% -61.27% -53.83% -34.44%
EBIT Growth		 -42.12% -13.87% 3.04% -11.21% -12.70% -25.19% -34.84% -70.25% -60.58% -53.47% -44.10%
NOPAT Growth		 -34.84% -9.66% -0.98% -18.34% -10.55% -14.92% -23.03% -52.72% -51.98% -54.01% -29.53%
Net Income Growth		 -43.04% -13.27% 5.18% -9.09% -9.87% -24.23% -36.26% -69.74% -59.75% -52.87% -67.11%
EPS Growth		 -42.42% -12.50% 18.48% 24.49% 21.28% 11.11% -12.00% -43.24% -17.57% -13.75% -9.52%
Operating Cash Flow Growth		 -28.23% -5.37% 33.96% 15.50% -17.54% 3.73% -196.81% 33.27% -50.47% -99.96% -18.53%
Free Cash Flow Firm Growth		 -56.25% 8.88% 21.64% 49.08% 48.57% 52.02% -26.94% -23.26% 3.92% -124.37% 469.68%
Invested Capital Growth		 63.03% 21.98% -2.97% -38.33% -28.53% -47.66% 1.89% -132.78% -109.16% -74.36% -898.18%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 4.24% 2.15% 2.80% -24.07% 3.14% -8.55% -4.58% -55.73% 8.78% -3.55% 8.60%
EBIT Q/Q Growth		 4.50% 2.48% 2.96% -23.05% 3.22% -8.33% -4.52% -55.36% 8.72% -3.54% 1.86%
NOPAT Q/Q Growth		 1.85% 1.65% -4.10% -17.75% 8.30% -2.24% -11.45% -46.16% 8.75% -3.61% 6.27%
Net Income Q/Q Growth		 4.44% 3.41% 4.29% -23.48% 3.76% -9.22% -4.98% -53.81% 9.42% -4.51% -14.77%
EPS Q/Q Growth		 4.08% 4.26% 16.67% 1.33% 0.00% -8.11% -5.00% -26.19% 17.92% -4.60% -1.10%
Operating Cash Flow Q/Q Growth		 15.11% 9.45% 54.89% -143.69% -18.09% 25.83% -39.07% 45.21% -166.27% 1.44% 17.56%
Free Cash Flow Firm Q/Q Growth		 7.74% 18.88% 16.04% 18.96% 6.83% 24.31% -122.11% 21.31% 27.37% -76.76% 465.97%
Invested Capital Q/Q Growth		 19.09% -4.25% -40.78% -8.67% 38.01% -29.88% 15.28% -129.38% 61.43% 296.27% -3,688.34%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 109.60%
Interest Burden Percent		 98.96% 98.02% 96.68% 97.02% 96.48% 97.27% 97.70% 96.72% 95.98% 96.89% 103.38%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -43.65% -49.49% -46.24% -53.69% -62.64% -77.89% -79.33% -68.90% -90.84% -125.90% -150.50%
Cash Return on Invested Capital (CROIC)		 -446.81% -397.29% -569.64% -460.81% -379.18% -438.79% -674.43% 0.00% 0.00% -1,577.97% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -43.65% -49.49% -46.24% -53.69% -62.64% -77.89% -79.33% -68.90% -90.84% -125.90% -150.50%
Return on Equity Simple (ROE_SIMPLE)		 -54.25% -63.89% -49.18% 0.00% -68.31% -87.88% -122.26% 0.00% -82.04% -116.71% -121.18%
Net Operating Profit after Tax (NOPAT)		 -18 -18 -19 -22 -20 -21 -23 -34 -31 -32 -30
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.48% -2.49% -1.33% -2.60% -3.73% -6.06% -4.71% -5.97% -6.38% -8.71% -11.37%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -26.20% - - - -20.11%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -23 -23 -22 -27 -26 -28 -30 -46 -42 -44 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -23 -22 -22 -27 -26 -28 -30 -46 -42 -43 -40
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.84 0.87 1.06 1.81 2.48 2.55 6.15 2.32 3.60 3.31 3.03
Price to Tangible Book Value (P/TBV)		 1.84 0.87 1.06 1.81 2.48 2.55 6.15 2.32 3.60 3.31 3.03
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 7.17 0.11 1.90 12.20 13.84 16.76 36.12 0.00 0.00 108.17 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.03
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.03
Financial Leverage		 -0.91 -0.89 -0.93 -0.91 -0.87 -0.87 -0.91 -0.98 -0.95 -0.94 -1.39
Leverage Ratio		 1.08 1.10 1.09 1.12 1.13 1.17 1.16 1.14 1.16 1.21 1.67
Compound Leverage Factor		 1.07 1.07 1.06 1.09 1.09 1.14 1.14 1.10 1.11 1.17 1.73
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.37% 2.90%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.37% 2.90%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 96.63% 97.10%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.03
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.82 1.46
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.03
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.04 -0.03
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.09 1.96
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.04 -0.03
Altman Z-Score		 8.80 1.96 4.71 5.81 7.14 3.50 7.69 7.56 10.36 5.19 -0.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 17.51 13.36 16.55 11.46 10.60 7.25 5.44 9.90 8.55 6.87 10.44
Quick Ratio		 14.60 10.80 14.79 9.94 8.72 5.81 3.95 9.23 7.78 6.13 9.89
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -27 -22 -18 -15 -14 -11 -23 -18 -13 -24 87
Operating Cash Flow to CapEx		 -2,471.96% -10,726.04% -61,926.67% -32,805.80% -445,500.00% -9,670.73% -25,064.55% -12,381.15% -47,317.65% -19,624.75% -25,733.07%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.50
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.50
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.54
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 22 22 13 12 16 11 13 -3.82 -1.47 2.89 -104
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 8.70 3.88 -0.39 -7.24 -6.42 -10 0.24 -15 -18 -8.38 -117
Enterprise Value (EV)		 161 2.46 24 142 223 189 469 268 447 313 191
Market Capitalization		 303 125 196 291 346 292 545 479 621 444 440
Book Value per Share		 $6.70 $5.85 $7.49 $4.71 $4.07 $3.33 $2.56 $4.90 $4.04 $3.10 $2.94
Tangible Book Value per Share		 $6.70 $5.85 $7.49 $4.71 $4.07 $3.33 $2.56 $4.90 $4.04 $3.10 $2.94
Total Capital		 165 144 184 161 139 114 89 207 173 139 149
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.68 4.34
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.68 4.34
Net Debt		 -142 -122 -172 -149 -123 -103 -76 -210 -174 -131 -249
Capital Expenditures (CapEx)		 0.92 0.19 0.02 0.07 0.01 0.21 0.11 0.12 0.09 0.20 0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 19 18 8.84 7.92 12 7.68 9.39 -7.52 -5.05 -5.67 -11
Debt-free Net Working Capital (DFNWC)		 161 140 181 157 136 111 85 203 169 130 242
Net Working Capital (NWC)		 161 140 181 157 136 111 85 203 169 130 242
Net Nonoperating Expense (NNE)		 4.62 4.14 2.44 4.10 4.95 6.83 5.82 11 9.49 10 18
Net Nonoperating Obligations (NNO)		 -142 -122 -172 -149 -123 -103 -76 -210 -174 -131 -249
Total Depreciation and Amortization (D&A)		 0.55 0.46 0.41 0.29 0.26 0.22 0.21 0.22 0.23 0.23 3.15
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.94) ($0.90) ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92)
Adjusted Weighted Average Basic Shares Outstanding		 24.56M 24.60M 28.28M 27.89M 34.41M 34.57M 34.72M 36.79M 46.23M 46.70M 52.64M
Adjusted Diluted Earnings per Share		 ($0.94) ($0.90) ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92)
Adjusted Weighted Average Diluted Shares Outstanding		 24.56M 24.60M 28.28M 27.89M 34.41M 34.57M 34.72M 36.79M 46.23M 46.70M 52.64M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 24.60M 24.62M 34.17M 34.23M 34.40M 34.56M 42.19M 42.74M 43.22M 49.42M 49.72M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -18 -19 -22 -20 -21 -23 -34 -31 -32 -30
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -15.06
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.58
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -15.11
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.62
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About KalVista Pharmaceuticals' Financials

When does KalVista Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, KalVista Pharmaceuticals' fiscal year ends in April. Their fiscal year 2024 ended on April 30, 2024.

How has KalVista Pharmaceuticals' net income changed over the last 2 years?

KalVista Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$126.64 million in 2024, rising from -$82.34 million in 2022. The previous period was -$92.91 million in 2023.

What is KalVista Pharmaceuticals's operating income?
KalVista Pharmaceuticals's total operating income in 2024 was -$140.45 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $140.45 million
How has KalVista Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, KalVista Pharmaceuticals' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does KalVista Pharmaceuticals have?

KalVista Pharmaceuticals' total liabilities were at $28.82 million at the end of 2024, a 30.0% increase from 2023, and a 53.4% increase since 2022.

How much cash does KalVista Pharmaceuticals have?

In the past 2 years, KalVista Pharmaceuticals' cash and equivalents has ranged from $30.73 million in 2022 to $56.24 million in 2023, and is currently $31.79 million as of their latest financial filing in 2024.

How has KalVista Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, KalVista Pharmaceuticals' book value per share changed from 7.54 in 2022 to 4.90 in 2024, a change of -35.1%.


Related Companies

This page (NASDAQ:KALV) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners
The Last Time This Happened, Americans Lost Billions
Wall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...
Banyan Hill Publishing | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored
Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...
Paradigm Press | Sponsored
Musk’s AI Masterplan – Our #1 AI Stock to Buy Now
Did Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...
Behind the Markets | Sponsored
DOGE officially begins retirement transformation
Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...
Altimetry | Sponsored
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
‘Wheels Are Falling Off’ the U.S. Stock Market
The last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...
Stansberry Research | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored